Jci_page_head_homepage_01 Jci_page_head_homepage_02
Biva M. Desai, Jennifer Oliver-Krasinski, Diva D. De Leon, Cyrus Farzad, Nankang Hong, Steven D. Leach, Doris A. Stoffers
Published in Volume 117, Issue 4
J Clin Invest. 2007; 117(4):971–977 doi:10.1172/JCI29988
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2
Cre-mediated recombination is restricted to the acinar cell lineage in TAM-treated ElastaseCreERT2Tg/+Rosa26r+/– mice.

ElastaseCreERT2 mouse pancreata from 16-week-old animals stained with X-gal (A, B, FH, J, and K), anti–Cre recombinase antiserum (red stain; C, L, and N), anti-amylase (green stain; D), or anti–cytokeratin 19 (red stain in E, GI, and K; green stain in M and N) without TAM treatment (A) and after 21 days of TAM treatment (BN). Arrowheads indicate centroacinar cells identified by cytokeratin-19 immunoreactivity (I and M) but no β-galactosidase activity (J) or Cre recombinase immunoreactivity (L). Original magnification, ×200 (AH); ×400 (IK); ×1,000 (LN).